Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T63024 Target Info
Target Name NF-kappa-B-activating kinase (TBK1)
Synonyms TANK-binding kinase 1; T2K; Serine/threonine-protein kinase TBK1; NAK
Target Type Patented-recorded Target
Gene Name TBK1
Biochemical Class Kinase
UniProt ID
TBK1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2012010826
Title Pyrimidine Compounds As Inhibitors of Protein Kinases Ikk Epsilon and/or Tbk-1, Processes for Their Preparation, and Pharmaceutical Compositions Containing Them.
Abstract C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases and/or TBK-1 : in which: R1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R3 and R4 independently represents a hydrogen atom or a C1-4 alkyl group.
Applicant(s) Domainex Limited
Representative Drug(s) D00PFT Drug Info IC50 < 1 nM Click to Show More [1]
2 D02EHR Drug Info IC50 < 1 nM [1]
3 D0YU2R Drug Info IC50 = 1 to 2 nM [1]
4 D09FGW Drug Info IC50 = 43467 nM [1]
5 D09WTI Drug Info N.A. [1]
6 D0D2LC Drug Info N.A. [1]
7 D0IF3G Drug Info N.A. [1]
8 D0JU7T Drug Info N.A. [1]
9 D0SM9Y Drug Info N.A. [1]
Patent ID WO2009030890
Title Pyrimidine Compounds for The Treatment of Cancer, Septic Shock and/or Primary Open Angle Glaucoma.
Abstract The present invention relates to the use of certain pyrimidine compounds to inhibit, for example, TBKl and/or IKK epsilon and which may therefore find application in treating cancer septic shock and/or Primary open Angle Glaucoma (POAG).
Applicant(s) University Court of the University of Dundee
United States Patent and Trademark Office (USPTO)
Patent ID US20120238540
Title Amino-Pyrimidine Compounds As Inhibitors of Ikk Epsilon and/or Tbk1.
Abstract The invention relates to certain amino-pyrimidine compounds that inhibit IKK epsilon and/or TBK1, methods of making such compounds, pharmaceutical compositions comprising such compounds, and the use of these compounds in treating a variety of diseases and disorders.
Applicant(s) Myrexis
Representative Drug(s) D09JVJ Drug Info N.A. Click to Show More [1]
2 D0IF0T Drug Info N.A. [1]
3 D0J4GP Drug Info N.A. [1]
4 D0SA6L Drug Info N.A. [1]
5 D0TK5U Drug Info N.A. [1]
References  Top
REF 1 TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.